Farmak JSC, the leading manufacturer of neurological and endocrinologic drugs in Ukraine, has developed and launched on the market a new antiepileptic drug, Meditan® (active ingredient: gabapentin) that comes in capsules.
Meditan® is intended for treatment of partial epileptic seizures with or without secondary generalization in adults and children (in combination with other antiepileptic drugs for children over 6 or as a monotherapy for children over 12). The new drug may also be used for treatment of associated nerve pain in adults with diabetic neuropathy and postherpetic neuralgia.
Farmak, as a member of the European Generic Medicines Association (EGA) – Medicines for Europe – and the Association of “Manufacturers of Drugs of Ukraine” (the AMDU), advocates for the creation of a coordination group at the Office of the President of Ukraine to prevent a shortage of medicines in Ukraine during the pandemic. […]
The pharmaceutical company JSC “Farmak” considers the possibility of launching the manufacture of products, in particular, diagnostic test kits, to combat coronavirus spread. “Now we analyse the possibility of arranging the release of supportive care products, disinfectants and antiseptics, diagnostic test kits, protective medical products, including masks, ...
Farmak reinvests 95% of its profits in the development. “We have never paid more than 5% of our profits as dividends. We have reinvested everything in the development. Due to this, Farmak’s capitalization can be estimated at $850 million to $1 billion today. If I sell the shares that I hold, I will earn a […]